Dario Trapani, Medical oncologist at the European Institute of Oncology (IEO), shared a post by Salvador Santiesteban, Medical Oncologist from the National Institute of Medical Sciences and Nutrition on X, adding:
“Inconsistent trial-based definitions, ‘confusion’ with amenorrhea and historical reliance on surrogate metrics vs pharmacodynamics has resulted in complexity where gonadal suppression in breast cancer is a clinical consideration; it’s biochemical in prostate cancer.”
Quoting Salvador Santiesteban‘s post:
“Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO | JCO BCSM.”
Authors: Catherine M. Kelly, et al.
Dario Trapani is a medical oncologist at the European Institute of Oncology (IEO) and a researcher in the Department of Oncology and Hemato-oncology at the University of Milan. He previously served as a Postdoctoral Researcher at the Dana-Farber Cancer Institute, and is focused on population health research.
